The third-generation tyrosine kinase inhibitor (TKI) ponatinib exerts a strong anti-neoplastic effect in all stages of chronic myeloid leukemia (CML) as well as in Philadelphia(Ph)-positive acute lymphoblastic leukemia (ALL). It is capable of suppressing the kinase activity of BCR-ABL1 carrying any
No takes yet. Share an insight, caveat, or question.
Byrgazov et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: